Premium
Suspected Carbamazepine‐Induced Hepatotoxicity
Author(s) -
MoralesDiaz Marta,
PinillaRoa Elizabeth,
Ruiz Inés
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.3.252.30918
Subject(s) - carbamazepine , medicine , adverse effect , anticonvulsant , population , hepatitis , dose , drug , epilepsy , intensive care medicine , anesthesia , pharmacology , psychiatry , environmental health
Carbamazepine is a potent anticonvulsant agent with proven efficacy in the treatment of partial and tonic‐clonic seizures. An epileptic child treated with therapeutic dosages of carbamazepine developed severe hepatitis and hepatic insufficiency. She had a positive response to withdrawal of the drug and administration of corticosteroids. The Roussel UCLAF method for estimating causality of the adverse event was applied for an acute hepatocellular problem, with a final score of 8. This method has advantages over other tools because it involves many clinical factors that give additional guides to clinicians in patients with liver injury, but it must be adapted for adverse events in the pediatric population.